Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

Prognostic factors of carcinoma of the ampulla of Vater after surgery

verfasst von: Jianguo Zhou, Qian Zhang, Peng Li, Yi Shan, Dongbing Zhao, Jianqiang Cai

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to investigate the prognostic factors of carcinoma of the ampulla of Vater (CAV) after surgery. The clinicopathological factors related to the recurrence and prognosis of 162 CAV patients after surgical resection were retrospectively analyzed using univariate and multivariate methods. The in-hospital mortality rate was 4.32 % and the 5-year disease-free survival and overall survival of the 162 subjects were 55.1 and 51.7 %, respectively. Univariate analysis revealed that an advanced T stage (P = 0.002), lymph nodal metastasis (P = 0.002), poor differentiation (P = 0.006), tumor size (P = 0.033), tumor stage (P = 0.001), carbohydrate antigen (CA) 199 serum levels (P = 0.000), pancreatic invasion (P = 0.001), chemotherapy/radiation therapy (P = 0.006), and jaundice (P = 0.012) were factors that significantly affected the prognosis of CAV. Multivariate analysis showed that the pancreatic invasion (P = 0.009), lymph nodal metastasis (P = 0.009), and increased CA199 serum level (P = 0.001) were independent risk factors of recurrence. The pancreatic invasion, lymph nodal metastasis, and increased CA199 serum level are key prognostic factors of CAV after surgery.
Literatur
1.
Zurück zum Zitat Neugut AI, Jacobson JS, Rella VA. Prevalence and incidence of colorectal adenomas and cancer in asymptomatic persons. Gastrointest Endosc Clin N Am. 1997;7:387–99.PubMed Neugut AI, Jacobson JS, Rella VA. Prevalence and incidence of colorectal adenomas and cancer in asymptomatic persons. Gastrointest Endosc Clin N Am. 1997;7:387–99.PubMed
2.
Zurück zum Zitat Barauskas G, Gulbinas A, Pranys D, et al. Tumor-related factors and patient’s age influence survival after resection for ampullary adenocarcinoma. J Hepatobiliary Pancreat Surg. 2008;15:423–8.PubMedCrossRef Barauskas G, Gulbinas A, Pranys D, et al. Tumor-related factors and patient’s age influence survival after resection for ampullary adenocarcinoma. J Hepatobiliary Pancreat Surg. 2008;15:423–8.PubMedCrossRef
3.
Zurück zum Zitat Al Ustwani O, Iancu D, Yacoub R, Iyer R. Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol. 2012;3:97–104.PubMedCentralPubMed Al Ustwani O, Iancu D, Yacoub R, Iyer R. Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol. 2012;3:97–104.PubMedCentralPubMed
4.
5.
Zurück zum Zitat O’Connell JB, Maggard MA, Manunga Jr J, et al. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 2008;15:1820–7.PubMedCrossRef O’Connell JB, Maggard MA, Manunga Jr J, et al. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 2008;15:1820–7.PubMedCrossRef
6.
Zurück zum Zitat Yoon YS, Kim SW, Park SJ, et al. Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann Surg. 2005;242:92–100.PubMedCrossRef Yoon YS, Kim SW, Park SJ, et al. Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann Surg. 2005;242:92–100.PubMedCrossRef
7.
Zurück zum Zitat Shiba H, Misawa T, Fujiwara Y, et al. Glasgow prognostic score predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of vater. Anticancer Res. 2013;33:2715–21.PubMed Shiba H, Misawa T, Fujiwara Y, et al. Glasgow prognostic score predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of vater. Anticancer Res. 2013;33:2715–21.PubMed
9.
10.
Zurück zum Zitat Clary BM, Tyler DS, Dematos P, et al. Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. Surgery. 2000;127:628–33.PubMedCrossRef Clary BM, Tyler DS, Dematos P, et al. Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. Surgery. 2000;127:628–33.PubMedCrossRef
11.
12.
13.
Zurück zum Zitat Lee SY, Jang KT, Lee KT, et al. Can endoscopic resection be applied for early stage ampulla of Vater cancer? Gastrointest Endosc. 2006;63:783–8.PubMedCrossRef Lee SY, Jang KT, Lee KT, et al. Can endoscopic resection be applied for early stage ampulla of Vater cancer? Gastrointest Endosc. 2006;63:783–8.PubMedCrossRef
14.
Zurück zum Zitat Yoon SM, Kim MH, Kim MJ, et al. Focal early stage cancer in ampullary adenoma: surgery or endoscopic papillectomy? Gastrointest Endosc. 2007;66:701–7.PubMedCrossRef Yoon SM, Kim MH, Kim MJ, et al. Focal early stage cancer in ampullary adenoma: surgery or endoscopic papillectomy? Gastrointest Endosc. 2007;66:701–7.PubMedCrossRef
15.
Zurück zum Zitat Dixon E, Vollmer Jr CM, Sahajpal A, et al. Transduodenal resection of peri-ampullary lesions. World J Surg. 2005;29:649–52.PubMedCrossRef Dixon E, Vollmer Jr CM, Sahajpal A, et al. Transduodenal resection of peri-ampullary lesions. World J Surg. 2005;29:649–52.PubMedCrossRef
16.
Zurück zum Zitat Hatzaras I, George N, Muscarella P, et al. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17:991–7.PubMedCentralPubMedCrossRef Hatzaras I, George N, Muscarella P, et al. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17:991–7.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg. 2003;138:941–8.PubMedCrossRef Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg. 2003;138:941–8.PubMedCrossRef
18.
Zurück zum Zitat de Paiva Haddad LB, Patzina RA, et al. Lymph node involvement and not the histopathologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. J Gastrointest Surg. 2010;14:719–28.PubMedCrossRef de Paiva Haddad LB, Patzina RA, et al. Lymph node involvement and not the histopathologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. J Gastrointest Surg. 2010;14:719–28.PubMedCrossRef
19.
Zurück zum Zitat Qiao QL, Zhao YG, Ye ML, et al. Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg. 2007;31:137–43.PubMedCrossRef Qiao QL, Zhao YG, Ye ML, et al. Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg. 2007;31:137–43.PubMedCrossRef
20.
Zurück zum Zitat Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. 2010;14:379–87.PubMedCrossRef Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. 2010;14:379–87.PubMedCrossRef
21.
Zurück zum Zitat Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140:764–72.PubMedCrossRef Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140:764–72.PubMedCrossRef
22.
Zurück zum Zitat Roland CL, Katz MH, Gonzalez GM, et al. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg. 2012;16:2056–63.PubMedCrossRef Roland CL, Katz MH, Gonzalez GM, et al. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg. 2012;16:2056–63.PubMedCrossRef
23.
Zurück zum Zitat Sierzega M, Nowak K, Kulig J, et al. Lymph node involvement in ampullary cancer: the importance of the number, ratio, and location of metastatic nodes. J Surg Oncol. 2009;100(1):19–24.PubMedCrossRef Sierzega M, Nowak K, Kulig J, et al. Lymph node involvement in ampullary cancer: the importance of the number, ratio, and location of metastatic nodes. J Surg Oncol. 2009;100(1):19–24.PubMedCrossRef
24.
Zurück zum Zitat Botsios D, Zacharakis E, Lambrou I, et al. Our local experience with the surgical treatment of ampullary cancer. Int Semin Surg Oncol. 2005;2:16.PubMedCentralPubMedCrossRef Botsios D, Zacharakis E, Lambrou I, et al. Our local experience with the surgical treatment of ampullary cancer. Int Semin Surg Oncol. 2005;2:16.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Lee JH, Whittington R, Williams NN, et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys. 2000;47:945–53.PubMedCrossRef Lee JH, Whittington R, Williams NN, et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys. 2000;47:945–53.PubMedCrossRef
26.
Zurück zum Zitat Beger HG, Treitschke F, Gansauge F, et al. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg. 1999;134:526–32.PubMedCrossRef Beger HG, Treitschke F, Gansauge F, et al. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg. 1999;134:526–32.PubMedCrossRef
27.
Zurück zum Zitat Hsu HP, Yang TM, Hsieh YH, et al. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol. 2007;14:50–60.PubMedCrossRef Hsu HP, Yang TM, Hsieh YH, et al. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol. 2007;14:50–60.PubMedCrossRef
28.
Zurück zum Zitat Zhou G, Chiu D, Qin D, et al. The efficacy evaluation of cryosurgery in pancreatic cancer patients with the expression of CD44v6, integrin-β1, CA199, and CEA. Mol Biotechnol. 2012;52:59–67.PubMedCrossRef Zhou G, Chiu D, Qin D, et al. The efficacy evaluation of cryosurgery in pancreatic cancer patients with the expression of CD44v6, integrin-β1, CA199, and CEA. Mol Biotechnol. 2012;52:59–67.PubMedCrossRef
29.
Zurück zum Zitat Zhou G, Niu L, Chiu D, et al. Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-α and TSGF after cryosurgery in pancreatic cancer patients. Biotechnol Lett. 2012;34:1235–41.PubMedCrossRef Zhou G, Niu L, Chiu D, et al. Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-α and TSGF after cryosurgery in pancreatic cancer patients. Biotechnol Lett. 2012;34:1235–41.PubMedCrossRef
30.
Zurück zum Zitat Zhou J, Hsu CC, Winter JM, et al. Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol. 2009;92:244–8.PubMedCentralPubMedCrossRef Zhou J, Hsu CC, Winter JM, et al. Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol. 2009;92:244–8.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Narang AK, Miller RC, Hsu CC, et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital–Mayo Clinic collaborative study. Radiat Oncol. 2011;6:126.PubMedCentralPubMedCrossRef Narang AK, Miller RC, Hsu CC, et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital–Mayo Clinic collaborative study. Radiat Oncol. 2011;6:126.PubMedCentralPubMedCrossRef
Metadaten
Titel
Prognostic factors of carcinoma of the ampulla of Vater after surgery
verfasst von
Jianguo Zhou
Qian Zhang
Peng Li
Yi Shan
Dongbing Zhao
Jianqiang Cai
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1153-9

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.